The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: In vitro and in vivo

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2229-2248

  Wang, Chao ^a   Wang, Xin ^a   Zhong, Ting ^a   Zhao, Yang ^a   Zhang, Wei Qiang ^a   Ren, Wei ^a   Huang, Dan ^a   Zhang, Shuang ^a   Guo, Yang ^a   Yao, Xin ^a   Tang, Yi Qun ^b   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Clotted plasma protein; Lysolipid containing thermosensitive liposomes; Targeting; Tumor homing peptide Cys Arg Glu Lys Ala (CREKA)

Indexed keywords

CYSTEINYLARGINYLGLUTAMYLLYSYLALANINE; DOXORUBICIN; LIPOSOME; PLASMA PROTEIN; POLYPEPTIDE; THERMOSENSITIVE LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CYSTEINYL-ARGINYL-GLUTAMYL-LYSYL-ALANYL; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; BREAST ADENOCARCINOMA; CANCER TISSUE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; ENCAPSULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HEAT SENSITIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE; STROMA; TRANSITION TEMPERATURE; TUMOR STROMA; TUMOR VASCULARIZATION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HEAT; MCF-7 CELL LINE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PROCEDURES; THERMOTHERAPY;

MUS MUSCULUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; MCF-7 CELLS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928167947     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S79840     Document Type: Article

References (56)

1. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science. 1985;227:1059-1061.
2. Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997;15:1271-1275.
3. Ye F, Wu X, Jeong EK, et al. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem. 2008;19:2300-2303.
4. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999;96:8663-8668.
5. Ahmad S, Ansari AA. Therapeutic roles of heparin anticoagulants in cancer and related disorders. Med Chem. 2011;7:504-517.
6. Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A. 2007;104:932-936.
7. Agemy L, Sugahara KN, Kotamraju VR, et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood. 2010;116:2847-2856.
8. Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine. 2009;5:73-82.
9. Kruse AM, Meenach SA, Anderson KW, Hilt JZ. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications. Acta Biomater. 2014;10:2622-2629.
10. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. 2012;17:160-166.
11. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
12. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197-1201.
13. Meers P. Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev. 2001;53:265-272.
14. Pedersen PJ, Adolph SK, Subramanian AK, et al. Liposomal formulation of retinoids designed for enzyme triggered release. J Med Chem. 2010;53:3782-3792.
15. Hatakeyama H, Murata M, Sato Y, et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J Control Release. 2014;173:43-50.
16. Yuba E, Tajima N, Yoshizaki Y, Harada A, Hayashi H, Kono K. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy. Biomaterials. 2014;35:3091-3101.
17. Alvarez-Lorenzo C, Bromberg L, Concheiro A. Light-sensitive intelligent drug delivery systems. Photochem Photobiol. 2009;85:848-860.
18. Seo HJ, Kim JC. Light-sensitive liposomes containing coumarin-proteinoid conjugate. J Nanosci Nanotechnol. 2012;12:4044-4050.
19. Ibsen S, Benchimol M, Simberg D, Schutt C, Steiner J, Esener S. A novel nested liposome drug delivery vehicle capable of ultrasound triggered release of its payload. J Control Release. 2011;155:358-366.
20. Sutton JT, Raymond JL, Verleye MC, Pyne-Geithman GJ, Holland CK. Pulsed ultrasound enhances the delivery of nitric oxide from bubble liposomes to ex vivo porcine carotid tissue. Int J Nanomedicine. 2014;9:4671-4683.
21. Cool SK, Geers B, Roels S, et al. Coupling of drug containing liposomes to microbubbles improves ultrasound triggered drug delivery in mice. J Control Release. 2013;172:885-893.
22. Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387-4398.
23. Li L, ten Hagen TL, Haeri A, et al. A novel two-step mild hyperthermia for advanced liposomal chemotherapy. J Control Release. 2014;174:202-208.
24. Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65:1784-1802.
25. Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274-279.
26. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther. 2004;3:1311-1317.
27. Tagami T, May JP, Ernsting MJ, Li SD. A thermosensitive liposome prepared with a Cu2-gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J Control Release. 2012;161:142-149.
28. Tagami T, Ernsting MJ, Li SD. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release. 2011;154:290-297.
29. Agarwal A, Mackey MA, El-Sayed MA, Bellamkonda RV. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano. 2011;5:4919-4926.
30. Tagami T, Ernsting MJ, Li SD. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release. 2011;152:303-309.
31. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science. 1979;204:188-191.
32. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202:1290-1293.
33. Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta. 2005;1716:77-96.
34. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother. 2009;10:333-343.
35. Lindner LH, Hossann M, Vogeser M, et al. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release. J Control Release. 2008;125:112-120.
36. Landon CD, Park JY, Needham D, Dewhirst MW. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J. 2011;3:38-64.
37. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60:6950-6957.
38. Banno B, Ickenstein LM, Chiu GN, et al. The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J Pharm Sci. 2010;99:2295-2308.
39. Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release. 2011;153:187-194.
40. Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release. 2010;143:265-273.
41. Yu KF, Zhang WQ, Luo LM, et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:2473-2485.
42. Du R, Zhong T, Zhang WQ, et al. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Int J Nanomedicine. 2014;9:3091-3105.
43. Yudina A, de Smet M, Lepetit-Coiffé M, et al. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J Control Release. 2011;155:442-448.
44. Kono K, Ozawa T, Yoshida T, et al. Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials. 2010;31:7096-7105.
45. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112-1116.
46. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J. 2002;367:729-740.
47. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63:7400-7409.
48. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 2002;62:2034-2042.
49. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465-473.
50. Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9:1-6.
51. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-234.
52. Kim D, Lee ES, Oh KT, Gao ZG, Bae YH. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small. 2008;4:2043-2050.
53. Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72:5566-5575.
54. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159.
55. Ren Y, Zhang H, Chen B, et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine. 2012;7:2261-2269.
56. Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys. 2002;6:309-314.